Related Experiment Videos
Tumor imaging with monoclonal antibodies
A Bischof Delaloye1, B Delaloye
1Nuclear Medicine Division, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Seminars in Nuclear Medicine
|April 1, 1995
Summary
Immunoscintigraphy shows promise for targeting human tumors, with radiolabeled monoclonal antibodies achieving over 70% sensitivity and 80% specificity in gastrointestinal and ovarian cancers. Further research is needed for lung and breast cancer detection.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceuticals
Background:
- Monoclonal antibodies (mAbs) face challenges in tumor cell penetration due to immune complexity and tumor microenvironment.
- Strategies like using antibody fragments and in vivo labeling aim to improve mAb delivery and targeting.
Observation:
- Radiolabeled mAbs demonstrate high sensitivity (>70%) and specificity (>80%) for gastrointestinal and ovarian cancers, detecting occult tumors.
- Immunoscintigraphy is more accurate than structural imaging for pelvic recurrence detection.
- Liver metastasis detection rates vary significantly (10-90%) due to potential tracer uptake in normal liver tissue.
Findings:
- Despite low absolute tumor uptake, immunoscintigraphy with radiolabeled mAbs is effective for specific cancers.
- Fusion of imaging modalities may enhance early detection of recurrent and metastatic disease.
- European studies show promising results in melanoma, but data for lung and breast cancers are limited.
Implications:
- Immunoscintigraphy offers a valuable functional imaging tool for cancer detection and recurrence monitoring.
- Further development of antibody engineering and labeling techniques could broaden its clinical application.
- Expanding research into understudied cancers like lung and breast cancer is crucial for wider adoption.